Recruiting
Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes
A pragmatic electronic health record (EHR) based randomized controlled trial to evaluate the utility of providing Ultromics EchoGo analysis results and recommendations for HF risk prevention therapies using an EHR embedded clinical decision support tool.
ClinicalTrials.gov IDNCT06593314
PhaseNA
Enrollment800
SponsorUniversity of Texas Southwestern Medical Center
AgeNo minimum reported
SexALL
Conditions studied
Heart Failure, Diabetes
About this study
A pragmatic electronic health record (EHR) based randomized controlled trial to evaluate the utility of providing Ultromics EchoGo analysis results and recommendations for HF risk prevention therapies using an EHR embedded clinical decision support tool.
Interventions
- Behavioral: Message with EchoGo — This alert will inform the provider that the patient has subclinical HFpEF
- Behavioral: Standard Message — This alert will inform the provider of guideline directed treatment options for patients with diabetes to prevent heart failure.
Primary outcomes
- Frequency of prescription of SGLT-2i medication at outpatient clinic visits over 3 months follow-up (3-month follow-up)
- Frequency of prescription of SGLT-2i medication at outpatient clinic visits over 6 months follow-up (3-month follow-up)
Eligibility information
Clinical cohort inclusion exclusion criteria:
Inclusion Criteria:
* Patients with diagnosis of Type 2 diabetes and High WATCH DM score.
* Echocardiogram available in last 6-months.
Exclusion Criteria:
* History of HF
* Not eligible for prescription of new GLP-1RA or SGLT2i or ns-MRA
Corresponding providers to patients identified by the above inclusion exclusion criteria will be included in the clinical trial of the decision support tool.
Study locations
- UT Southwestern Medical Center, Dallas, Texas 75235 United States
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.